# Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction

Study · id `cardio:ct-nct03753269` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03753269](<https://clinicaltrials.gov/study/NCT03753269>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03753269

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 600 participants.

## Technical summary

Registry record NCT03753269. Randomized; double masking; primary purpose treatment. Start 2019-07-01 (anticipated); primary completion 2022-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT03753269, source copy `cardio:ctgov-nct03753269-2018-11-26`, retrieved 2026-10-26)
- Planned start: 2019-07-01 (anticipated) (ClinicalTrials.gov record NCT03753269, source copy `cardio:ctgov-nct03753269-2018-11-26`, retrieved 2026-10-26)
- Primary completion: 2022-06-30 (anticipated) (ClinicalTrials.gov record NCT03753269, source copy `cardio:ctgov-nct03753269-2018-11-26`, retrieved 2026-10-26)
- Completion: 2022-12-30 (anticipated) (ClinicalTrials.gov record NCT03753269, source copy `cardio:ctgov-nct03753269-2018-11-26`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03753269-2018-11-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction
- Condition: ST Segment Elevation Myocardial Infarction
- Intervention (Drug): Fasudil Hydrochloride
- Intervention (Drug): Placebo saline
- Lead sponsor: RenJi Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: RenJi Hospital (`cardio:org-renji-hospital`)

## Provenance

Content hash: 3dc597936374fbd9e2a07647134f9847170a4cec5892266d56bad7a35869db27
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
